BioSyent

BioSyent Inc.

Q3/YTD 2025 Results

NOVEMBER 20, 2025

PRESENTED BY: RENÉ GOEHRUM
PRESIDENT AND CEO

DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

All values in CAD unless otherwise indicated.



BioSyent

FeraMAX® MD
Therapeutic
Thérapeutique
150

gelclair®

RepaGyn®

Cathejell®

FeraMAX® MD
Powder
Poudre
15

inofolic® MD

FeraMAX®
Maintenance
Entretien
45

Proktis-M®

Tibella®
Tibelia Global

Protect-It®
The *Natural* Choice

Sales, EBITDA and NIAT
Quarter ended September 30th (Q3)



Sales, EBITDA and NIAT

Nine months ended September 30th (YTD)



Sales growth from Canadian Pharma, International Pharma and Legacy Businesses

EBITDA[1] Margin: 29% to Sales

NIAT Margin: 21% to Sales

Q3/YTD 2025 Sales Summary ($)

	Q3 '25 Sales ($)	Q3 '25 vs. Q3 '24 (%)	YTD '25 Sales ($)	YTD '25 vs. YTD '24 (%)
Canadian Pharma ($)	$9,864k	+19%	$28,351k	+16%
Cathejell®		-1%		+5%
Combogesic®		-23%		-25%
FeraMAX® Pd		+20%		+16%
Gelclair®		-62%		-49%
Inofolic®		+21%		+63%
RepaGyn®		+2%		-1%
Tibella® (Canada)		+32%		+36%
International Pharma ($)	$1,154k	+94%	$3,135k	+316%
Legacy ($)	$1,204k	+83%	$1,894k	+73%
Total Company ($)	$12,222k	+28%	$33,380k	+27%

BioSyent

Fully Diluted Earnings per Share (TTM)



2025 YTD Highlights

Tibelia Global

- YTD 2025: First Tibelia® Global shipments made by BioSyent: ~$1.8 million in incremental revenue
  - Further orders shipping Q4 2025

- Mar/Jun/Sep 2025: Paid quarterly dividends of $0.05/share (+11% increase vs. 2024)
- Nov 2025: Q4 2025 Dividend of $0.05/share declared

- Apr 2025: FeraMAX® named #1 recommended iron supplement in Canada for **tenth** consecutive year

- YTD 2025: 19,500 shares repurchased and cancelled under NCIB

BioSyent

- Most recommended iron supplement in Canada - pharmacists and physicians - **10** consecutive years(1)
- Continued innovation and expansion of FeraMAX® product line for iron health

(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recommendations

Innovations, Product Launches and Acquisitions

Tibella®	Jul 2020
FeraMAX® Pd	Oct 2020
FeraMAX® Pd Therapeutic 150	Nov 2020
Combogesic®	Dec 2020
FeraMAX® Pd Powder 15	Oct 2021
FeraMAX® Pd Maintenance 45	Mar 2023
Inofolic®	Aug 2023
Gelclair®	Nov 2023
Tibelia® Global	Sep 2024
New endocrinology asset	TBD
FeraMAX® Pd products in development	TBD

15 Years of Profitable Growth (and Counting!)



f/d shares: 14,336,194 → 11,575,410

BioSyent

Cash Balance & Return on Equity (“RoE”)

Trailing Twelve Months ended September 30th



- Zero Debt
- TTM Cash from Operations of **$8.1M**
- TTM NCIB share buybacks: **$3.8M**
- TTM Dividends of **$2.2M**
- Sep 30/25 Working Capital of **$28.9M**
- Execution of strategy drives TTM RoE of **22%**

BioSyent

Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit <u>growth</u> & portfolio <u>diversification</u>.

Capital Light,
Cash-Generating
Business Model



Quarterly Dividends
$6.7 M to Date
Q4’22 – Q4’25

Share Buybacks
$22.6 M to Date
3.1 million shares repurchased since 2018

- 7 new product launches in Canada since July 2020
- Tibelia® / Tibella® (tibolone) Global Acquisition in Sept 2024

Stock Information

As at November 18, 2025

Exchange & Trading Symbol	TSXV: RX
Nov 18, 2025 Closing Stock Price (CAD) (TSXV):	**$10.76**
52 Week Hi/Low (TSXV):	**$12.49 / $9.20**
Issued Common Shares:	11,475,447
Treasury – RSU Shares in Trust	(213,165)
Outstanding Common Shares:	11,262,282
Options Outstanding	104,415
RSUs Outstanding	208,713
Fully Diluted Common Shares:	**11,575,410**
P/E Ratio :	**14.43**
EV/EBITDA :	**8.09**

PROFITABLE.

WELL CAPITALIZED.

GROWTH ASSETS.

FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.

Reconciliation of EBITDA to NIAT

1.EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

A reconciliation of EBITDA to NIAT for the three months, nine months, and trailing twelve months ended September 30, 2025 and 2024 is provided in the table below:

	Three Months (Q3) Ended September 30		Nine Months (YTD) Ended September 30		Trailing Twelve Months (TTM) Ended September 30	
	2025	2024	2025	2024	2025	2024
EBITDA	**3,632,399**	**2,849,636**	**9,594,195**	**7,101,900**	**11,835,307**	**8,752,201**
Add: Interest Income	231,389	256,890	621,333	828,498	881,421	1,170,681
Less: Depreciation - Property, Equipment	(66,353)	(70,298)	(201,335)	(209,107)	(273,448)	(286,071)
Amortization of Intangible Assets	(135,852)	(46,545)	(424,694)	(144,521)	(588,901)	(188,909)
Interest Expense	(12,141)	(14,579)	(37,875)	(45,181)	(51,846)	(61,575)
Income Tax Expense	(967,102)	(667,210)	(2,531,180)	(1,874,679)	(3,168,895)	(2,278,626)
NIAT	**2,682,340**	**2,307,894**	**7,020,444**	**5,656,910**	**8,633,638**	**7,107,701**